Laduviglusib
Cat. No.: IBDI-434256
Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy.
Size (Solid + Solvent): 10 mM * 1 mL ready for reconstitution
Online Inquiry
Product Details
| Target |
GSK-3 | Wnt | β-catenin | Autophagy |
| Molecular Weight |
465.34 |
| Appearance |
Solid |
| Synonyms |
CHIR-99021, CT99021 |
| Purity |
99.71% |
Storage & Handling
| Shipping |
Room temperature in continental US. May vary elsewhere. |
| Storage |
Powder: -20°C/3 years; 4°C/2 years
In solvent: -80°C/6 months; -20°C/1 month |
| Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.
